Western Alliance Bancorporation (WAL) Reaches $60.42 High on Feb, 15; Therapix Biosciences Limited Ads (TRPX) Shorts Increased By 15.67%

February 15, 2018 - By Darrin Black

Therapix Biosciences Limited Ads (NASDAQ:TRPX) had an increase of 15.67% in short interest. TRPX’s SI was 83,400 shares in February as released by FINRA. Its up 15.67% from 72,100 shares previously. With 27,000 avg volume, 3 days are for Therapix Biosciences Limited Ads (NASDAQ:TRPX)’s short sellers to cover TRPX’s short positions. The SI to Therapix Biosciences Limited Ads’s float is 12.71%. The stock decreased 5.84% or $0.3249 during the last trading session, reaching $5.2351. About 3,168 shares traded. Therapix Biosciences Ltd. (NASDAQ:TRPX) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock of Western Alliance Bancorporation (NYSE:WAL) reached all time high today, Feb, 15 and still has $62.84 target or 4.00% above today’s $60.42 share price. This indicates more upside for the $6.37 billion company. This technical setup was reported by Barchart.com. If the $62.84 PT is reached, the company will be worth $254.96 million more. The stock increased 0.72% or $0.43 during the last trading session, reaching $60.42. About 235,669 shares traded. Western Alliance Bancorporation (NYSE:WAL) has risen 29.08% since February 15, 2017 and is uptrending. It has outperformed by 12.38% the S&P500.

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. The company has market cap of $17.49 million. The Company’s drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome ; and BrainBright Pharma, which develops THX-ULD01, a drug candidate based on an ultra-low dose of dronabinol for the treatment for mild cognitive impairment. It currently has negative earnings. The firm was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013.

Among 13 analysts covering Western Alliance Bancorp (NYSE:WAL), 13 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Western Alliance Bancorp had 48 analyst reports since September 8, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, January 4 by Sandler O’Neill. The firm has “Hold” rating given on Tuesday, January 9 by Wells Fargo. The rating was upgraded by DA Davidson to “Buy” on Thursday, February 11. The rating was maintained by Macquarie Research with “Outperform” on Monday, October 19. The rating was maintained by Barclays Capital on Monday, July 24 with “Overweight”. On Sunday, August 27 the stock rating was maintained by Jefferies with “Buy”. Keefe Bruyette & Woods maintained the shares of WAL in report on Thursday, December 21 with “Buy” rating. Keefe Bruyette & Woods maintained it with “Buy” rating and $58.0 target in Tuesday, October 3 report. The firm earned “Overweight” rating on Tuesday, October 13 by Piper Jaffray. The stock of Western Alliance Bancorporation (NYSE:WAL) earned “Buy” rating by Wells Fargo on Monday, January 29.

Since August 16, 2017, it had 1 insider buy, and 9 insider sales for $10.18 million activity. $173,578 worth of Western Alliance Bancorporation (NYSE:WAL) shares were sold by Theisen Randall S. The insider SNYDER DONALD D sold $223,880. 29 shares valued at $1,722 were bought by LATTA ROBERT P on Thursday, February 1. $225,960 worth of Western Alliance Bancorporation (NYSE:WAL) was sold by MCAUSLAN ROBERT REOCH. Sarver Robert Gary sold $5.52 million worth of stock or 100,000 shares. 5,000 shares were sold by Sohn Sung Won, worth $279,450 on Wednesday, October 25. BOYD WILLIAM S sold $555,462 worth of Western Alliance Bancorporation (NYSE:WAL) on Monday, October 23.

Western Alliance Bancorporation operates as the holding firm for Western Alliance Bank that provides various banking products and related services primarily in Arizona, California, and Nevada. The company has market cap of $6.37 billion. The firm offers deposit products, including checking accounts, savings accounts, and money market accounts, as well as fixed-rate and fixed maturity certificates of deposit accounts. It has a 19.49 P/E ratio. It also offers commercial and industrial loan products, such as working capital lines of credit, inventory and accounts receivable lines, mortgage warehouse lines, equipment loans and leases, and other commercial loans; commercial real estate loans, which are secured by multi-family residential properties, professional offices, industrial facilities, retail centers, hotels, and other commercial properties; construction and land development loans for single family and multi-family residential projects, industrial/warehouse properties, office buildings, retail centers, medical office facilities, and residential lot developments; and consumer loans.

Investors sentiment increased to 1.32 in 2017 Q3. Its up 0.30, from 1.02 in 2017Q2. It is positive, as 20 investors sold Western Alliance Bancorporation shares while 85 reduced holdings. 42 funds opened positions while 97 raised stakes. 84.78 million shares or 0.26% more from 84.56 million shares in 2017Q2 were reported. 4,450 were accumulated by Invest Counselors Of Maryland Limited Liability Corporation. Aimz Invest Advisors Limited Com reported 0.23% of its portfolio in Western Alliance Bancorporation (NYSE:WAL). Alliancebernstein Limited Partnership holds 811,345 shares. Tiaa Cref Mgmt Ltd Liability owns 647,934 shares. Epoch Investment Prns Inc holds 0.16% or 910,707 shares in its portfolio. Raymond James Svcs Advsr Inc invested in 0% or 4,145 shares. United Cap Advisers Limited Liability Company owns 6,810 shares. Citadel Limited Liability Corp holds 0.06% or 1.51M shares in its portfolio. Rafferty Asset Mngmt Lc invested in 20,549 shares. Cwm Lc accumulated 3,000 shares. Brandywine Global Invest Mngmt Ltd Llc invested in 61,930 shares. Bb&T stated it has 21,513 shares. Symphony Asset Management Ltd Liability Corporation, California-based fund reported 12,934 shares. Westwood Gru Inc reported 2.30 million shares stake. Jpmorgan Chase owns 1.90 million shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: